| Efficacy of levetiracetam in Huntington disease. | |
| | |
MedLine Citation:
|
PMID: 16340384 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Levetiracetam (LEV) is a novel antiepileptic drug characterized by a wide spectrum of action; no pharmacologic interaction and poor adverse events are reported. In animal models, effects of LEV are observed in basal ganglia. The aim of this study was to evaluate the efficacy of LEV in reducing involuntary movements in subjects affected by Huntington disease (HD). METHODS: This was a single-center, short-term, open-label, controlled study. Patients had LEV as add-on therapy for 6 months. In the first visit patients were rated according to the Unified Huntington Disease Rating Scale. Every 2 months they were submitted to all these tests. LEV was added at the dose of 500 mg twice daily for the first 2 months and then the dosage was increased until 1000 mg twice daily for the next 4 more months. The authors enrolled 22 patients: 15 were assigned to the LEV group and 7 were enrolled as control subjects. RESULTS: No serious adverse events were experienced by the treated patients. After 6 months of treatment patients on LEV showed a significant reduction of involuntary movements, with a slight improvement of functional capacity compared with the control group. CONCLUSION: Results of this short-term, prospective, controlled study indicates that in HD patients, LEV is effective in reducing involuntary movements, thus improving the quality of life. |
| | |
Authors:
|
Marina de Tommaso; Olimpia Di Fruscolo; Vittorio Sciruicchio; Nicola Specchio; Claudia Cormio; Maria Fara De Caro; Paolo Livrea |
Related Documents
:
|
14705724 - Characterization of perioperative seizures and epilepsy following aneurysmal subarachno... 20398284 - Vns in drug resistant epilepsy: preliminary report on a small group of patients. 12638104 - Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter inve... 2122814 - Quantitative changes in faecal microflora preceding necrotising enterocolitis in premat... 16829444 - Metabolic effects of glucose compared with invertose and a mixture of fructose, glucose... 10973334 - Clinical and angiographic results with the multi-link stent implanted under intravascul... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 28 ISSN: 0362-5664 ISO Abbreviation: Clin Neuropharmacol Publication Date: 2005 Nov-Dec |
Date Detail:
|
Created Date: 2005-12-12 Completed Date: 2006-03-02 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 280-4 Citation Subset: IM |
Affiliation:
|
Department of Neurological and Psychiatric Sciences, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy. m.detommaso@neurol.uniba.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Analysis of Variance Anticonvulsants / therapeutic use* Case-Control Studies Disability Evaluation Dose-Response Relationship, Drug Drug Administration Schedule Drug Evaluation Eye Movements / drug effects Female Follow-Up Studies Humans Huntington Disease / drug therapy* Male Middle Aged Neurologic Examination Piracetam / analogs & derivatives*, therapeutic use Severity of Illness Index Treatment Outcome Walking |
| Chemical | |
Reg. No./Substance:
|
0/Anticonvulsants; 33996-58-6/etiracetam; 7491-74-9/Piracetam |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy of topiramate and valproate in chronic migraine.
Next Document: A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: i...